TrialBlood2012

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

Alireza Eghtedar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.